Erlotinib for Treatment of Psoriasis

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

The purpose of this study is to determine whether erlotinib is effective in the treatment of psoriasis.

Key facts

Study ID

NCT01006096

Run by

Northwestern University

People needed

0

Last updated by the study team

2014-11-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of moderate to severe psoriasis
• Must have documented moderate to severe psoriasis by the Physician's Global Assessment (PGA) and the Psoriasis Area Severity Index (PASI)
• Must be able to swallow tablets
• Must be able to provide written informed consent
• Subjects with reproductive potential (menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study and thirty days after discontinuation of study drug. Women of childbearing potential must provide negative pregnancy test (serum or urine) within 14 days prior to randomization.

You may not qualify if…

• Use of concurrent agents/therapies for psoriasis
• Bilirubin > 3 X ≥ ULN or moderate to severe hepatic impairment
• Pregnant or breast-feeding females
• Subjects currently receiving other anticancer treatments
• Subjects currently receiving other biologic treatments
• Subjects currently receiving blood thinners (warfarin or heparin)
• Subjects who currently smoke
• Subjects with other skin disease which in the opinion of the investigator, would inhibit the ability to use the PGA and PASI evaluation methods

Where it is running

• Northwestern University Feinberg School of Medicine Department of Dermatology — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.